13F Holdings
中文EN

PTHS Pelthos Therapeutics Inc.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1919246 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-231.0%
TTM EPS YoY-32.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin83.2%
Operating margin-101.6%
Net margin-152.2%
FCF margin-63.5%
EBITDA margin-98.9%

Returns

ROE-299.8%
ROA-61.2%
ROIC (approx.)-408.1%
Asset turnover0.40x

Leverage & solvency

Liabilities / assets104.8%
Debt / equity—
Current ratio1.78x
Interest coverage-6.26x

Cash quality & payout

Operating cash flow / net income0.41x
Accruals ratio-35.9%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue$16.80M$0——
Cost of revenue$3.99M$0——
Gross profit$12.81M$0——
R&D expense$1.23M$1.18M$2.58M$391,730
SG&A expense$42.45M$6.39M$2.74M$1.10M
Operating income-$32.43M-$7.57M-$6.86M-$2.32M
Interest expense$3.01M$786,000$309,094$135,630
Pretax income-$50.71M-$7.96M-$7.38M-$2.46M
Income tax-$7.39M$0——
Net income-$43.32M-$7.96M-$7.38M-$2.46M
EBITDA-$31.70M-$7.57M——
EPS (basic)-23.04-14.27-5.785.65
EPS (diluted)-23.04-14.27-5.78—
Weighted avg. shares (diluted)1.88M557,4471.28M—
Balance sheet
Cash & equivalents$17.97M$513,000$96,000$55,074
Receivables$8.86M$0——
Inventory$23.57M$0——
Current assets$53.41M$1.37M$96,391$55,074
PP&E, net$9.59M$0——
Goodwill$24.68M$0——
Intangibles$39.47M$0——
Total assets$130.40M$1.37M$96,391$55,074
Current liabilities$25.99M$4.08M$6.54M$3.76M
Total liabilities$91.52M$4.08M$6.54M$3.76M
Shareholders' equity$38.88M-$2.71M-$6.45M-$3.71M
Shares outstanding3.23M610,3893.91M1.11M
Cash flow statement
Operating cash flow-$22.59M-$5.79M-$981,031-$1.57M
Capital expenditure$99,000$0——
Free cash flow-$22.69M-$5.79M——
Investing cash flow-$5.24M$0——
Financing cash flow$45.34M$6.21M$1.02M$1.62M
Depreciation & amortization$729,000$0——
Stock-based compensation$5.46M$1.80M$1.73M$110,146
Share buybacks$0$75,000——

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.